 "Aurobindo Pharma gains over 10% on positive growth outlook")
Even with muted outlook for the pharma sector, Aurobindo Pharma, today, rose as much as 10.6% in today’s trade after the company yesterday said is confident about FY18 growth despite weak Q4 earnings. The company posted a 4% dip in consolidated net profit at Rs 532.22 crore for the fourth quarter ended March 2017 as compared to Rs 554.51 crore posted during the same period of the previous fiscal.
The healthcare company, in its conference call, said that it is less worried about pricing pressure in the US and the price erosion is likely to be 7-8%, which is far less than its peers that expect in double digits. The company also expects intensity of pricing pressure to taper off in the coming quarters.
The firm also informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2017, inter alia, has considered and approved second interim dividend of 125% i.e. Rs.1.25 (Rupee one and paise twenty five only) per equity share of Re.1/- each on the equity share capital of the Company for the financial year 2016-17.
“The total dividend, including the second interim dividend for the financial year 2016-17 will aggregate to 250% i.e. Rs.2.50 (Rupee two and paise fifty only) per equity share of Re.1/- each on the equity share capital of the Company,” a filing on BSE said.
Higher than usual volumes were witnessed on the counter with 4.38 lakh shares trading in the counter so far on BSE, compared with average daily volumes of 2.57 lakh shares in the past one quarter. The stock had hit a high of Rs 547.45 and a low of Rs 506 so far during the day.
At 11:24 am the scrip was trading 8.33% higher at Rs 556.5 as compared to 0.2% gain on BSE Sensex. It had hit a high and low of Rs 568.25 and Rs 506 so far in today’s trade.
The stock had hit a record high of Rs 895 on October 6, 2016. Shares of the company fell 15.24% in the past one month till 29 May 2017, as against 3.98% gains in the Sensex. The scrip had also underperformed the market in past one quarter, falling 24.14% as compared to Sensex's 8.23% gains.
BSE Healthcare index has falled over 10% in the month of May and analysts believe any bad news — be it on the regulatory front (US FDA plant inspections), delay in approvals or pricing pressures on the current basket of products — could lead to further correction in the range of 5-10 per cent. The top five companies in the pharma space, which used to trade at 22-25 times one-year forward earnings, are now available at 17-18 times. Read full report here
The healthcare company, in its conference call, said that it is less worried about pricing pressure in the US and the price erosion is likely to be 7-8%, which is far less than its peers that expect in double digits. The company also expects intensity of pricing pressure to taper off in the coming quarters.
The firm also informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2017, inter alia, has considered and approved second interim dividend of 125% i.e. Rs.1.25 (Rupee one and paise twenty five only) per equity share of Re.1/- each on the equity share capital of the Company for the financial year 2016-17.
“The total dividend, including the second interim dividend for the financial year 2016-17 will aggregate to 250% i.e. Rs.2.50 (Rupee two and paise fifty only) per equity share of Re.1/- each on the equity share capital of the Company,” a filing on BSE said.
Higher than usual volumes were witnessed on the counter with 4.38 lakh shares trading in the counter so far on BSE, compared with average daily volumes of 2.57 lakh shares in the past one quarter. The stock had hit a high of Rs 547.45 and a low of Rs 506 so far during the day.
At 11:24 am the scrip was trading 8.33% higher at Rs 556.5 as compared to 0.2% gain on BSE Sensex. It had hit a high and low of Rs 568.25 and Rs 506 so far in today’s trade.
The stock had hit a record high of Rs 895 on October 6, 2016. Shares of the company fell 15.24% in the past one month till 29 May 2017, as against 3.98% gains in the Sensex. The scrip had also underperformed the market in past one quarter, falling 24.14% as compared to Sensex's 8.23% gains.
BSE Healthcare index has falled over 10% in the month of May and analysts believe any bad news — be it on the regulatory front (US FDA plant inspections), delay in approvals or pricing pressures on the current basket of products — could lead to further correction in the range of 5-10 per cent. The top five companies in the pharma space, which used to trade at 22-25 times one-year forward earnings, are now available at 17-18 times. Read full report here
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%